I'm not betting against them but they're clearly going in a different direction. We don't want them to follow through anyway. MANF is worth billions. There's no penalty if it's arranged to be mutual and if AMBS is re-emerging focuses on MANF, it's a guaranty at this point the deal is off completely or altered to give us back MANF. I never believed it from the start, I always thought this was a ploy to put MANF behind a layer where debtors could not access it until we were ready to work on it.

TOMDF success is going to be one of the sources of cash or assets that allow us to take MANF into the clinic. But the phrase mid term is key. There won't be any lympro or other no-covid diagnostic revenue at Todos for awhile. It's pure potential at this point and that's ok.

The lack of Elto or ESS talk is telling. I'm guessing continued psychogenics disruption and ESS may remain with Healixa, who knows.